Submitted by Anonymous (not verified) on 10 June 2026 - 15:06
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 18, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 18, Status: Authorised